TORONTO, Canada and DENVER, Colorado, February 19, 2019 -- MJardin Group, Inc. (“MJardin” or “the Company”) (CSE: MJAR) (OTCQX: MJARF), a global leader in cannabis production, announced today that, effective immediately, its Board of Directors has appointed Mr. Adrian T. Montgomery as Chairman of the Board of Directors and interim Chief Executive Officer, and has appointed Mr. Lorne Sugarman to the Board of Directors.
MJardin Group Commences Trading on OTCQX Best Market
MJARDIN GROUP, INC. ANNOUNCES FILING OF 2018 ANNUAL FINANCIAL STATEMENTS OF SUMTRA DIVERSIFIED INC.
MJardin Group Announces Definitive Agreement for Joint Venture with Rama First Nation
DENVER, January 10, 2019 – MJardin Group, Inc. (“MJardin” or the “Company”) (CSE:MJAR), a leader in cannabis management, announced today that it has completed a definitive agreement for its previously announced joint venture with Rama First Nation to bring large-scale cannabis cultivation, extraction, and retail to Rama, Ontario and the surrounding region. The partnership’s first major project will be the construction of a large-scale cannabis production facility which will create at least 100 permanent jobs for Rama and area residents.
MJardin Group Issues CEO Letter to Company Stakeholders
DENVER, January 8, 2019 – MJardin Group, Inc. (“MJardin” or the “Company”) (CSE:MJAR), a leader in cannabis management, today issued a letter to stakeholders from Rishi Gautam, Chairman and Chief Executive Officer, to provide an update on the Company’s business and growth strategy. The letter can be found on the Company’s Investor Relations site and below.
MJardin Group Receives Its First Cannabis Sales License from Health Canada
MJardin Group Added to the CSE Composite Index
MJardin Group Announces Medical Cannabis Research Investment in Spain
Collaboration with Salamanca University and the Institute of Neuroscience of Castilla y León to Study the Benefits of Cannabinoids on Epilepsy and Schizophrenia.
DENVER, December 18, 2018 – MJardin Group, Inc. (“MJardin” or the “Company”) (CSE:MJAR), a leader in cannabis management, today announced its first medical cannabis research investment to fund two studies on the benefits of cannabinoids on epilepsy and schizophrenia.
MJardin Group Granted Cannabis Cultivation License by Health Canada for Nova Scotia Facility
DENVER, December 11, 2018 – MJardin Group, Inc. (“MJardin” or the “Company”) (CSE:MJAR), a leader in cannabis management, is pleased to announce that the recently opened cultivation and extraction facility in Lower Sackville, Nova Scotia owned by AtlantiCann Medical Inc. (“AMI”), in which MJardin has a 50% equity interest, has been granted a license by Health Canada for cannabis cultivation.
MJardin Group Announces Investment In DNA Genetics
DENVER, December 4, 2018 – MJardin Group, Inc. (“MJardin” or the “Company”) (CSE:MJAR), a leader in cannabis management, is pleased to announce the closing on November 26, 2018 of a $6 million minority investment in OG DNA Genetics Inc. (“DNA Genetics”), a globally recognized leader in cannabis with operations in California, Canada and Europe.